Parkinson disease treatment and motor complications

01Purpose and principlesWhat the treatment does and how it fits into care.

Levodopa remains the most effective symptomatic treatment for bradykinesia and rigidity. It is combined with a peripheral dopa-decarboxylase inhibitor as co-beneldopa or co-careldopa. Initial treatment is chosen around functional impact, age, cognition, occupational needs, comorbidity and the person's priorities rather than a fixed age threshold. Dopamine agonists and MAO-B inhibitors may postpone or reduce levodopa exposure for some, but generally provide less motor benefit and impose distinct sleep, hallucination, oedema and behavioural risks.

With disease progression, the therapeutic window narrows. Short duration of levodopa benefit creates end-of-dose wearing-off; gastric emptying and dietary competition can delay onset; excessive peaks provoke dyskinesia. A diary aligning exact dose, meals, mobility, tremor, freezing and involuntary movement is more informative than simply increasing the total daily amount. Strategies include smaller more frequent levodopa doses, formulation changes and adjunct enzyme or receptor therapies, all balanced against hallucination, hypotension and dyskinesia.

Advanced treatment targets levodopa-responsive symptoms that fluctuate despite best oral therapy. Apomorphine offers rescue injection or continuous infusion; deep-brain stimulation can improve selected motor fluctuations and tremor but not levodopa-unresponsive gait, cognition or speech; device-assisted levodopa delivery can smooth exposure. Selection requires movement-disorder, nursing, neuropsychological, therapy and surgical expertise. Exact products, conversions and pump settings follow current specialist and local formularies.

Key points

Offer levodopa when early motor symptoms affect quality of life; if they do not, discuss levodopa, a non-ergot dopamine agonist or an MAO-B inhibitor using individual risks and preferences.
Doses must be given at the person's established times, not merely standard drug-round times. Delayed or omitted levodopa can cause profound immobility, aspiration and a hyperpyrexia syndrome.
Wearing-off is predictable return of symptoms before the next dose; delayed-on reflects slow absorption, while sudden unpredictable immobility is an on-off phenomenon.
Peak-dose dyskinesia occurs when levodopa effect is greatest; diphasic dyskinesia appears as concentration rises and falls, so an accurate timing diary precedes dose manipulation.
For troublesome fluctuations despite optimal levodopa, specialist add-on choices include a dopamine agonist, MAO-B inhibitor or COMT inhibitor; amantadine may be considered for dyskinesia.
All dopaminergic therapy can cause impulse-control disorders, with higher risk from dopamine agonists; warn the patient and family about gambling, shopping, binge eating and hypersexuality before starting.
Hallucinations, daytime sleepiness, postural hypotension, confusion and compulsive behaviour may cause more harm than a modest motor gain, particularly in frailty or cognitive impairment.
Protein can alter levodopa absorption in some people with fluctuations, but dietary redistribution should be supervised so weight loss and malnutrition are not worsened.
Advanced options include intermittent or continuous apomorphine, deep-brain stimulation and commissioned intestinal or subcutaneous levodopa systems after multidisciplinary assessment.
Physiotherapy, occupational therapy, speech and language therapy, exercise, falls prevention and palliative approaches are treatments throughout the illness, not substitutes offered only when medicines fail.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

End-of-dose wearing-off

Slowness, tremor, pain, anxiety or dystonia returns predictably before the next levodopa dose and improves after it takes effect; a time-linked diary confirms the pattern.

Delayed or failed on

A scheduled dose takes unusually long to work or has no effect, often around constipation, gastroparesis, protein intake or inaccurate administration, but disease progression and adherence must also be reviewed.

Levodopa-induced dyskinesia

Choreiform or dystonic involuntary movement relates to peak or changing drug effect and must be distinguished from tremor, akathisia and functional movement before treatment is altered.

Impulse-control disorderRed flag

New gambling, spending, eating, sexual behaviour, hobbyism or compulsive medicine use may be concealed from the patient; collateral history and non-judgemental direct questions are essential.

Neuropsychiatric toxicityRed flag

Visual hallucinations, delusions, daytime sleepiness or confusion emerge after dose escalation, infection or cognitive decline. Physical triggers and the whole medicines list need review before antipsychotic treatment.

Withdrawal emergencyRed flag

Missed or abruptly stopped dopaminergic treatment is followed by severe rigidity, fever, dysphagia, autonomic instability, confusion and raised creatine kinase, resembling neuroleptic malignant syndrome.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Dose-symptom-meal diaryFirst step
Why
Map each exact dose against on-time, wearing-off, freezing, dyskinesia, sleep and food to classify the motor complication.
Interpretation and limitations
A reproducible relationship guides redistribution or add-on therapy. Separate peak-dose from diphasic movement and consider constipation or swallowing difficulty when absorption is erratic.
02
Comprehensive medicines reconciliation
Why
Prevent omitted dopaminergic doses and identify dopamine blockers, anticholinergic burden and medicines worsening hypotension or hallucination.
Interpretation and limitations
Record formulation, strength and personal administration times, including pumps and patches. Avoid metoclopramide and prochlorperazine where they exacerbate parkinsonism; check local antiemetic policy.
03
Functional and cognitive assessment
Why
Quantify whether motor benefit translates into walking, self-care, work and safety and whether cognition limits advanced therapy.
Interpretation and limitations
Assess timed mobility, falls, freezing, transfers, speech, swallowing, activities, mood, hallucinations and cognition in both on and off states where feasible.
04
Postural blood pressure and physical screen
Why
Find reversible contributors to falls, confusion and fluctuating function before escalating dopaminergic treatment.
Interpretation and limitations
Assess hydration, infection, constipation, pain, sleep and cardiac rhythm; dopaminergic and antihypertensive medicines can compound neurogenic orthostatic hypotension.
05
Advanced-therapy multidisciplinary assessment
Why
Determine levodopa responsiveness, neuropsychiatric suitability, carer capacity and procedural risk for pumps or surgery.
Interpretation and limitations
A levodopa challenge, diary, neuropsychology, brain imaging and therapy assessments may be used. Severe uncontrolled dementia, psychosis or levodopa-unresponsive axial disability can reduce expected benefit.
06
Acute deterioration tests
Why
Identify hyperpyrexia syndrome, aspiration, infection, renal injury and rhabdomyolysis after abrupt medicine disruption.
Interpretation and limitations
Check temperature, CK, renal profile, electrolytes, inflammatory markers, ECG, chest imaging and cultures as indicated while restoring dopaminergic delivery urgently.

04Treatment approachPreparation, options, escalation and aftercare.

01Early motor therapyMatch treatment to impactFirst stepA specialist has confirmed Parkinson disease and motor symptoms need treatment.

1Define which activities, discomfort or participation the person wants to improve and assess cognition, postural pressure, sleepiness, hallucination and impulse-control vulnerability.
2Offer levodopa when motor symptoms impair quality of life; for lesser impact, discuss levodopa, non-ergot dopamine agonist and MAO-B inhibitor with comparative benefits and harms.
3Record counselling on sleep attacks, driving, hallucinations and impulse-control behaviours, invite family observations with consent and arrange an early response and tolerability review.
4Refer for Parkinson-specific physiotherapy, occupational or speech-and-language assessment when balance, activity, communication, saliva or swallowing would benefit.

02Motor fluctuationClassify before addingMobility varies through the day or involuntary movements appear during established levodopa treatment.

1Create a several-day dose and symptom diary, reconcile exact timing and formulation and treat constipation, swallowing or administration problems that produce unreliable absorption.
2With specialist advice, optimise levodopa timing or dose size and then consider a dopamine agonist, MAO-B inhibitor or COMT inhibitor for off-time, discussing class-specific risks.
3For dyskinesia, distinguish peak-dose from diphasic patterns, consider levodopa redistribution and specialist amantadine, and measure whether reducing movement worsens useful on-time.
4Reassess hallucination, cognition, postural pressure, sleepiness and compulsive behaviour after every material change rather than focusing only on motor minutes.

03Hospital admissionKeep Parkinson medicines on timeA person with Parkinson disease is nil by mouth, vomiting, confused, perioperative or unable to swallow tablets.

1Obtain the home regimen, formulation and exact clock times immediately from the patient, carer, record or pharmacy and mark dopaminergic treatment as time critical.
2Contact the Parkinson specialist or pharmacist urgently for a nasogastric, dispersible, transdermal or other conversion plan; do not improvise dose equivalence or simply omit treatment.
3Avoid dopamine-blocking antiemetics and antipsychotics unless a specialist judges benefit, and monitor aspiration, delirium, rigidity, temperature, autonomic signs and mobility.
4If hyperpyrexia syndrome is suspected, restore dopaminergic therapy, give supportive and complication-directed care and involve neurology and critical care without delay.

04Advanced diseaseSelect device therapy by phenotypeDisabling off-time, tremor or dyskinesia persists despite optimised oral and transdermal treatment.

1Confirm that the target symptoms improve with levodopa, quantify off-time and dyskinesia and optimise best medical therapy with a movement-disorder specialist.
2Compare apomorphine, deep-brain stimulation and available commissioned levodopa-delivery systems against cognition, psychiatric status, frailty, surgical risk, manual ability and carer support.
3Set realistic goals and a device-specific monitoring and troubleshooting plan while continuing exercise, therapy, falls, swallowing, cognition, palliative and advance-care support.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Levodopa is the most effective motor treatment and is offered when early symptoms affect quality of life.

Co-beneldopa or co-careldopa

Start and titrate an immediate or modified-release preparation individually through the specialist treatment plan.

Give at the person's prescribed times and never stop abruptly; monitor nausea, hypotension, somnolence, hallucinations, dyskinesia and fluctuating response. Modified-release products are not milligram-for-milligram interchangeable.

Can treat early mild symptoms or reduce off-time as an adjunct to levodopa.

Non-ergot dopamine agonist

Pramipexole, ropinirole or rotigotine is titrated slowly using the product-specific licensed schedule.

Impulse-control disorders, sleep attacks, oedema, hallucinations, hypotension and withdrawal syndrome require explicit counselling; taper rather than stopping suddenly.

Offers modest early symptomatic benefit or reduces off-time alongside levodopa in selected patients.

MAO-B inhibitor

Rasagiline, selegiline or safinamide is prescribed at its licensed once-daily or product-specific dose.

Check serotonergic and sympathomimetic interactions, insomnia, dyskinesia and hepatic restrictions; safinamide has a different licensed place from the older agents.

Prolongs levodopa effect and can reduce end-of-dose wearing-off.

COMT inhibitor

Entacapone accompanies levodopa doses; opicapone is once daily, following the licensed specialist regimen.

May increase dyskinesia, diarrhoea, postural symptoms and urine discoloration; tolcapone has important liver toxicity and restricted specialist use.

May reduce troublesome levodopa-induced dyskinesia when regimen adjustment alone is insufficient.

Amantadine

Initiate and adjust under specialist advice, with dose reduction in impaired renal function and older frailty.

Confusion, hallucinations, ankle oedema, livedo reticularis and insomnia occur; renal accumulation is dangerous and sudden withdrawal can worsen Parkinson symptoms.

Provides rapid rescue from off episodes or continuous dopaminergic stimulation in advanced motor fluctuation.

Apomorphine

A specialist establishes antiemetic-supported test dosing, rescue injections or an individualised continuous infusion.

Severe nausea, hypotension, somnolence, nodules, haemolytic anaemia, hallucinations and impulse-control problems require a trained multidisciplinary service and blood monitoring.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

At each change, record on-time, off-time, freezing, dyskinesia, falls and target activities with exact dosing and meal timing rather than a global statement that mobility is worse.
Ask the patient and, with consent, a family member directly about gambling, spending, eating, sexual behaviour, medication overuse and repetitive hobbyism before and during dopaminergic therapy.
Measure lying and standing blood pressure and review hallucinations, cognition, daytime sleepiness, driving, oedema, weight, swallowing and constipation as treatment burden increases.
During admission, audit every dopaminergic administration against the home clock time and activate a non-oral plan early if swallowing or gastrointestinal absorption fails.
Use renal function for amantadine and relevant product-specific blood, liver, ECG or haematology monitoring for adjuncts and infusion therapies.
Review advanced-device benefit, hardware or skin complications, carer capacity and goals regularly; progression of levodopa-unresponsive symptoms may change the balance.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Timing is a dose

For a person with short-duration response, giving the correct tablet an hour late is a clinically significant prescribing error, not an administrative inconvenience.

Off can be non-motor

Anxiety, pain, sweating or cognitive slowing can recur before a dose and may represent wearing-off even without obvious tremor.

Dyskinesia is not failure

Involuntary movement may coexist with the patient's best mobility, so treatment seeks useful function rather than eliminating every extra movement.

Families identify compulsion

Reduced insight and shame mean impulse-control disorders are often found through carefully invited collateral history rather than spontaneous disclosure.

DBS treats selected circuits

Deep-brain stimulation improves levodopa-responsive fluctuation and tremor but does not reverse dementia, postural instability or swallowing that never responded to levodopa.

Nil by mouth is urgent

A perioperative plan must preserve dopaminergic delivery; waiting until rigidity develops creates aspiration, immobility and hyperpyrexia risk.

08Common pitfallsFrequent interpretation and management errors.

01
Prescribing levodopa four times daily without preserving the patient's exact established administration times.
02
Stopping a dopamine agonist abruptly after discovering an impulse-control disorder rather than arranging supervised reduction.
03
Increasing total levodopa for every fluctuation without classifying wearing-off, delayed-on and peak-dose or diphasic dyskinesia.
04
Using metoclopramide or prochlorperazine routinely in a patient whose parkinsonism may worsen with dopamine blockade.
05
Offering deep-brain stimulation for dementia, levodopa-unresponsive gait failure or symptoms already controlled by best medical therapy.
06
Treating hallucinations with a potent dopamine-blocking antipsychotic before checking infection, cognition and Parkinson medicines.